Recon: J&J, Protagonist tout phase 3 study wins for oral IL-23 therapy; Bayer buys Japanese rights to Cytokinetics’ heart drug Welcome to Regulatory Reconnaissance, your regulatory news and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results